Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Dec 20, 2013)
  • 8-K (Dec 17, 2013)
  • 8-K (Dec 13, 2013)
  • 8-K (Nov 27, 2013)
  • 8-K (Nov 5, 2013)
  • 8-K (Oct 8, 2013)

 
Other

MAKO SURGICAL CORP 8-K 2009

Documents found in this filing:

  1. 8-K
  2. 8-K
MAKO SURGICAL CORP. FORM 8-K DATED MAY 27, 2009
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


FORM 8-K


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 27, 2009

 


MAKO Surgical Corp.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-33966

20-1901148

(State or other jurisdiction of

incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

 

2555 Davie Road

Fort Lauderdale, Florida 33317

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (954) 927-2044

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 
 



Item 8.01.            Other Events

 

On May 27, 2009, Maurice R. Ferré, M.D., Chairman, Chief Executive Officer, and President of MAKO Surgical Corp. (the “Company”), entered into a pre-arranged stock trading plan to sell a portion of his shares of the Company’s common stock in accordance with the guidelines specified by Rule 10b5-1 under the Securities Exchange Act of 1934 and the Company’s insider trading policies. Rule 10b5-1 permits an officer or director to enter into a pre-arranged plan for buying or selling Company stock at a time when the officer or director is not in possession of material, nonpublic information about the Company. After adoption of a Rule 10b5-1 plan, the officer or director retains no further discretion in carrying out the trades under the plan, although the officer or director may later amend or terminate the plan. The existence of such a plan allows for personal holdings to be diversified in an orderly fashion from time to time, often as part of a personal financial, tax, or estate planning strategy.

 

The Rule 10b5-1 plan adopted by Dr. Ferré provides for the sale of up to 100,000 shares of the Company’s common stock at specified market prices commencing thirty days after adoption of the plan and continuing until all 100,000 shares are sold or December 31, 2010, whichever occurs first. Any transaction under this plan will be reported to the Securities and Exchange Commission in accordance with applicable securities laws, rules, and regulations.

 

The Company does not intend to report on Form 8-K any Rule 10b5-1 plans that may be adopted by any other officers or directors. In addition, the Company undertakes no obligation to report any modifications or terminations of any publicly announced trading plan, except to the extent as may be required by law.

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

MAKO Surgical Corp.

 

 

 

 

 

 

 

 

 

Date: May 28, 2009

By:

/s/ Menashe R. Frank

 

 

Menashe R. Frank, Senior Vice President,
General Counsel and Secretary





2



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki